Sophia Genetics closed an upsized underwritten public offering after strong investor demand, generating total gross proceeds of $57.5 million before underwriting discounts and commissions. The offering sold 12,104,900 ordinary shares at $4.75 per share after underwriters fully exercised an option for an additional 1,578,900 shares. Sophia said it plans to use the proceeds for working capital and general corporate purposes, including R&D support to expand features, applications and data modalities of its Sophia DDM platform. The company also pointed to sales and marketing efforts as part of the intended deployment. The oversubscribed result suggests continued market interest in precision diagnostics and data-driven genotyping platforms, particularly those positioned for clinical decision support workflows.